BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs
BIAL, a pharmaceutical company based in Portugal with locations across Europe and dedicated to R&D in CNS diseases, announced today that it has established a new affiliate in the United States of America, BIAL Biotech Investments Inc. (BIAL Biotech). This new research center focused on genetically-defined Parkinson’s disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.
António Portela, executive president of BIAL, reveals: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programs from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide. The development of this new research center in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”
This acquisition not only provides the company with a pipeline of new product candidates in Parkinson’s disease but also an experienced R&D team, led by Peter Lansbury, professor of neurology at Harvard Medical School and a recognized thought leader in the field of neurodegenerative diseases.
With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's disease, where the pharmaceutical company already has a significant market position.
The executive president of BIAL also points out: “The compounds we’ve acquired are based on genetics, a new field of research for us. The lead asset, which now has the code name 'BIA 28-6156/LTI-291', has an innovative mechanism of action and presents the potential of being a first disease-modifying therapy for a genetic subset of Parkinson’s disease. It has successfully completed a Phase I trial program and should be ready to start Phase II studies in 2021. We´re progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL.”
“We are happy to be part of BIAL and take the lead on the growth story in the US,” says Kees Been, former CEO of LTI and now CEO of BIAL Biotech. "With the commitment and resources of BIAL we will be able to accelerate our novel clinical and research programs as targeted and personalized treatment approaches for genetically-defined PD patients.”
“On behalf of the LTI shareholders, I want to express our enthusiastic endorsement of BIAL as a good home for the programs of LTI,” said Clay B. Thorp, General Partner, Hatteras Venture Partners. “This deal is a perfect fit and we have great confidence that the team, with the resources and commitment of BIAL, will advance LTI-291 and the other compounds rapidly to patients to treat this debilitating form of Parkinson’s disease.”
BIA 28-6156 / LTI-291 is a drug compound aimed at treating patients with GBA-Associated Parkinson’s diseases (GBA-PD) caused by an underlying mutation in the GBA1 gene. This genetic mutation affects approximately 10% to 15% of Parkinson’s disease patients (100,000-150,000 patients in the US) and is a validated risk factor that generally leads to an earlier age of disease onset and more rapid disease progression.
In addition to an upfront payment, the total value of the deal could reach up to 130 million dollars, based on attainment of a series of milestone payments as the assets progress through the clinic and into the market. Other financial terms will not be disclosed.
About BIAL Biotech
BIAL Biotech is a Center of Excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL, a pharmaceutical company based in Portugal with locations across Europe.
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle21.10.2020 12:00:00 EEST | Press release
Bacardi, the world’s largest family-owned spirits company, has made a giant leap forward in the fight against climate change and plastic pollution today, as it unveils plans to put the world’s most sustainable spirits bottle on shelf by 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005281/en/ Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle (Photo: Business Wire) The new 100% biodegradable bottle will replace 80 Million plastic bottles – 3,000 tons of plastic – currently produced by Bacardi across its portfolio of brands every year. This revolutionary move by Bacardi is possible thanks to its close collaboration with Danimer Scientific, a leading developer and manufacturer of biodegradable products. Petroleum-based plastics used by Bacardi today will be replaced by Danimer Scientific’s Nodax™ PHA, a biopolymer which derives from the natural oils of plant seeds such as palm,
1 GWh of Daily Solar Production Is Optimized and Monitored by Tigo Solutions Globally21.10.2020 12:00:00 EEST | Press release
This summer, Tigo Energy Inc.’s fleet of monitored module-level power electronics (MLPE) crossed a major milestone – more than 1 GWh of daily solar production. The fleet includes tens of thousands of communicating systems that span all seven continents on sites ranging from single kilowatt residential scale to multi-megawatt utility scale PV installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005322/en/ Tigo's fleet of monitored PV systems spans all 7 continents and generates more than one gigawatt-hour of energy per day. (Graphic: Business Wire) “This is a significant milestone that’s the result of years of hard work by our team and our amazing network of partners that literally span the globe,” said Zvi Alon, Chairman and CEO of Tigo Energy. The daily production is tracked using Tigo’s cloud monitoring platform, which has the most granular data visibility available in the market. End customers and installat
Lionbridge International Wins 3M EMEA Supplier of the Year Award21.10.2020 11:00:00 EEST | Press release
Lionbridge International, a global leader in localisation and AI training data solutions, was honored with the 2019 3M Supplier of the Year Award in recognition of the company’s contribution to improving 3M’s competitiveness. This year, 3M recognized 12 suppliers, among thousands in its global supply base, for world class performance in providing products and/or services. These suppliers were identified and rated based on strategic spend, contract compliance, actions taken to improve 3M’s relevance and overall supplier performance (quality, delivery, responsiveness, cost, and technology roadmaps). “We are truly delighted to receive this prestigious award as it recognizes our commitment and dedication to support 3M by providing agile communications which resonate locally and amplify their global brand,” said Corinne Saunders, EMEA Managing Director, Lionbridge. “Our partnership has evolved over many years to the global engagement we have today and this award showcases the trust, shared
Ooredoo Algeria Pushes to 10Gbps its Wireless Mobile Backhaul with SIAE MICROELETTRONICA21.10.2020 10:00:00 EEST | Press release
Ooredoo a leader in mobile services, together with SIAE MICROELETTRONICA, a leading supplier of microwave and millimetre wave radio for mobile backhauling, established another record in the country pushing mobile backhaul capacity to 10Gbps. Ooredoo Algeria is unceasingly working to maximise its mobile backhaul capacity, establishing one of the most technologically advance transport infrastructure in the region. This latest achievement is part of the ongoing e-band and multiband backhaul upgrade program to a multi-gigabit infrastructure. The 10Gbps link has been achieved by upgrading an existing link operating at the maximum channel bandwidth allowed in the country of 1GHz, to a 2+0 configuration over a single antenna, effectively doubling the link capacity. “Investing in new technologies is fundamental in building resilient networks capable of withstanding unexpected situation” says Abdelkrim Melab, Head of Transmission Engineering at Ooredoo Algeria, adding “this has been possible th
Vertical Group Holding: BNP Paribas Leadership MUST Come to Malta for Questioning in Case Alleging Anti-semitism and Corruption, Court Rules, Following Extended Legal Fight Over Their Attendance21.10.2020 10:00:00 EEST | Press release
BNP Paribas’ CEO and Chairman have been ordered to appear before a Maltese court, where they face questions about the French bank’s alleged involvement with a highly controversial deal in Malta, and about serious alleged ethical, legal and professional violations at the bank, Vertical Group Holding announces today. Jean-Laurent Bonnafé and Jean Lemierre, two of France’s highest-profile executives, will be pressed to give evidence as witnesses in court concerning their roles in an alleged plot by BNP Paribas to discredit a financier of British-Israeli background who had criticized the bank over its admitted involvement in multiple criminal activities, including money-laundering for pariah regimes. Jacob Agam, alongside Malta-based Vertical Group, the international private equity group he chairs, is bringing a civil lawsuit against both men and BNP itself for what he alleges was the bank’s deliberate and unlawful destruction of the business’s assets. BNP and the executives dispute the cl
MYbank Shortens Payment Cycles for Small and Micro Businesses in the Lead up to This Year’s 11.11 Global Shopping Festival21.10.2020 07:38:00 EEST | Press release
MYbank, a leading online private commercial bank in China with a focus on serving small and micro businesses, today announced a program to provide RMB 400 billion of collateral-free credit to businesses in need as they gear up for this year’s 11.11 Global Shopping Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020006336/en/ Leveraging Ant Group's technologies, MYbank has pioneered the “310 model” that enables SMEs to apply for collateral-free business loans that take less than three minutes to apply for on a mobile phone, less than one second to approve, and requires zero human intervention. (Photo: Business Wire) As part of the dedicated program, MYbank is offering a total of RMB 200 billion in short-term loans to help small and micro business owners overcome the economic impact of the COVID-19 pandemic. This enables business owners, particularly smaller vendors with more immediate capital needs, to receive pay
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom